Cardiff Oncology, Inc. (CRDF)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.76-13.07%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · CRDF
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
We are at a defining period for Cardiff as we prepare to initiate our registrational Phase 3 study in the first quarter of 2027.
Stated in 1 of 1 supplied quarters. Management reported: “The 30 mg onvansertib + FOLFIRI/bevacizumab (bev) arm achieved a confirmed objective response rate (ORR) of 72.2% compared to 43.2% across the combined standard-of-care (SoC) arms.” “We are at a defining period for Cardiff as we prepare to initiate our registrational Phase 3 study in the first quarter of 2027.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
““In April, we had a successful End ‑ of ‑ Phase 2 meeting with the FDA and aligned on the key design elements for our Phase 3 registrational trial.”
With strong clinical momentum, we remain focused on disciplined execution throughout the year.”
Stated in 1 of 1 supplied quarters. Management reported: “Operating results Total operating expenses were approximately $12.9 million for the three months ended March 31, 2026, a decrease of $1.6 million from $14.5 million for the same period in 2025.” “Net cash used in operating activities for the first quarter of 2026 was approximately $12.3 million, a decrease of approximately $0.5 million from $12.8 million for the same period in 2025.” Operating income was $-12.850 million in 2026-Q1.
“With strong clinical momentum, we remain focused on disciplined execution throughout the year.””
In parallel, we continue to strengthen the scientific foundation of our PLK1 inhibition strategy, supported by new preclinical data evaluating combination use with an antibody-drug conjugate, as well…
Stated in 1 of 1 supplied quarters. Management reported: “In parallel, we continue to strengthen the scientific foundation of our PLK1 inhibition strategy, supported by new preclinical data evaluating combination use with an antibody-drug conjugate, as well as ongoing single-agent and combination investigator-initiated studies across multiple cancer settings.”
“In parallel, we continue to strengthen the scientific foundation of our PLK1 inhibition strategy, supported by new preclinical data evaluating combination use with an antibody-drug conjugate, as well…”
Advance the selected onvansertib regimen toward a registrational Phase 3 study in first-line RAS-mutated metastatic colorectal cancer.
Provide detailed CRDF-004 Phase 2 results and communicate the regulatory path for onvansertib in first-line RAS-mutated mCRC.
Over the trailing year it converted 10.71x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
11 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.